International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-4. (Canceled)

- 5. (New) A method for detecting the presence of lung cancer cells in a biological sample comprising the steps of:
 - (a) detecting the level of mRNA expression in the biological sample of two or more cancer-associated markers selected from the group consisting of L762P, L550S, L587S, L984P, L552S, and L763P; and
- (b) comparing the level of mRNA expression detected in the biological sample for each marker to a predetermined cut-off value for each marker; wherein a detected level of expression above the predetermined cut-off value for one or more markers is indicative of the presence of lung cancer cells in the biological sample.
- 6. (New) A method for detecting the presence of lung cancer cells in a biological sample comprising the steps of:
 - (a) detecting the level of mRNA expression in the biological sample of two or more cancer-associated markers selected from the group consisting of L762P, L550S, L587S, and L984P; and
- (b) comparing the level of mRNA expression detected in the biological sample for each marker to a predetermined cut-off value for each marker; wherein a detected level of expression above the predetermined cut-off value for one or more markers is indicative of the presence of lung cancer cells in the biological sample.

International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

7. (New) The method of claim 6, wherein step (a) comprises detecting the level of mRNA expression using a nucleic acid hybridization technique.

- 8. (New) The method of claim 6, wherein step (a) comprises detecting the level of mRNA expression using a nucleic acid amplification method.
- 9. (New) The method of claim 8, wherein step (a) comprises detecting the level of mRNA expression using a nucleic acid amplification method selected from the group consisting of transcription-based amplification, polymerase chain reaction amplification (PCR), ligase chain reaction amplification (LCR), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA).
- 10. (New) The method of claim 6, wherein the L762P cancer-associated marker comprises a nucleic acid sequence set forth in SEQ ID NO: 1 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 2.
- 11. (New) The method of claim 6, wherein the L550S cancer-associated marker comprises a nucleic acid sequence set forth in SEQ ID NO: 5 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 6.
- 12. (New) The method of claim 6, wherein the L587S cancer-associated marker comprises a nucleic acid sequence set forth in SEQ ID NO: 26 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 27.
- 13. (New) The method of claim 6, wherein the L984P cancer-associated marker comprises a nucleic acid sequence set forth in SEQ ID NO: 3 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 4.

International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

14. (New) The method of claim 6, wherein the cancer is a small cell lung cancer or a non-small cell lung cancer.

- 15. (New) The method of claim 6, wherein the biological sample is a sample suspected of containing cancer-associated markers or cancer cells expressing such markers.
- 16. (New) The method of claim 15, wherein the biological sample is selected from the group consisting of a biopsy sample, lavage sample, sputum sample, serum sample, peripheral blood sample, lymph node sample, bone marrow sample, urine sample, and pleural effusion sample.
- 17. (New) A composition for detecting cancer cells in a biological sample comprising two or more of:
 - a) a first oligonucleotide that specifically hybridizes to L762P;
 - b) a second oligonucleotide that specifically hybridizes to L550S;
 - c) a third oligonucleotide that specifically hybridizes to L587S; and
 - d) a fourth oligonucleotide that specifically hybridizes to L984P.
- 18. (New) The composition of claim 17, wherein the first oligonucleotide specifically hybridizes to an L762P nucleic acid sequence set forth in SEQ ID NO: 1 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 2, the second oligonucleotide specifically hybridizes to an L550S nucleic acid sequence set forth in SEQ ID NO:5 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 6, the third oligonucleotide specifically hybridizes to an L587S nucleic acid sequence set forth in SEQ ID NO: 26 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 27, and the fourth oligonucleotide specifically hybridizes to an L984P nucleic acid sequence set forth in

International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

SEQ ID NO: 3 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 4.

19. (New) A diagnostic kit for detecting cancer cells in a biological sample comprising two or more of:

- a) a first oligonucleotide that specifically hybridizes to L762P;
- b) a second oligonucleotide that specifically hybridizes to L550S;
- c) a third oligonucleotide that specifically hybridizes to L587S; and
- d) a fourth oligonucleotide that specifically hybridizes to L984P.
- 20. (New) The kit of claim 19, wherein the first oligonucleotide specifically hybridizes to an L762P nucleic acid sequence set forth in SEQ ID NO: 1 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 2, the second oligonucleotide specifically hybridizes to an L550S nucleic acid sequence set forth in SEQ ID NO:5 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 6, the third oligonucleotide specifically hybridizes to an L587S nucleic acid sequence set forth in SEQ ID NO: 26 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 27, and the fourth oligonucleotide specifically hybridizes to an L984P nucleic acid sequence set forth in SEQ ID NO: 3 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 4.
- 21. (New) A composition for detecting cancer cells in a biological sample comprising two or more of:
 - a) a first primer pair that specifically hybridizes to L762P;
 - b) a second primer pair that specifically hybridizes to L550S;
 - c) a third primer pair that specifically hybridizes to L587S; and
 - d) a fourth primer pair that specifically hybridizes to L984P.

International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

22. (New) The composition of claim 21, wherein the first, second, third and fourth primer pairs are effective in a nucleic acid amplification method for amplifying all or a portion of an L762P nucleic acid sequence set forth in SEQ ID NO: 1 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 2, an L550S nucleic acid sequence set forth in SEQ ID NO:5 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 6, an L587S nucleic acid sequence set forth in SEQ ID NO: 26 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 27, and an L984P nucleic acid sequence set forth in SEQ ID NO: 3 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 4, respectively.

- 23. (New) A diagnostic kit for detecting cancer cells in a biological sample comprising two or more of:
 - a) a first primer pair that specifically hybridizes to L762P;
 - b) a second primer pair that specifically hybridizes to L550S;
 - c) a third primer pair that specifically hybridizes to L587S; and
 - d) a fourth primer pair that specifically hybridizes to L984P.
- 24. (New) The kit of claim 23, wherein the first, second, third and fourth primer pairs are effective in a nucleic acid amplification method for amplifying all or a portion of an L762P nucleic acid sequence set forth in SEQ ID NO: 1 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 2, an L550S nucleic acid sequence set forth in SEQ ID NO: 5 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 6, an L587S nucleic acid sequence set forth in SEQ ID NO: 26 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 27, and an L984P nucleic acid sequence set forth in SEQ ID NO: 3 or a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 4, respectively.

International Application No.: PCT/US2004/007451

International Filing Date: 10 March 2004

Preliminary Amendment

- 25. (New) A diagnostic kit for detecting cancer cells in a biological sample comprising two or more of:
 - a) a first antibody specific for an L762P protein;
 - b) a second antibody specific for an L550S protein;
 - c) a third antibody specific for an L587S protein; and
 - d) a fourth antibody specific for an L984P protein.
- 26. (New) The kit of claim 25, wherein the L762P protein comprises an amino acid sequence set forth in SEQ ID NO: 2, the L550S protein comprises an amino acid sequence set forth in SEQ ID NO: 6, the L587S protein comprises an amino acid sequence set forth in SEQ ID NO: 27, and the L984P protein comprises an amino acid sequence set forth in SEQ ID NO: 4.